Brief: Sagimet Biosciences Completes Enrollment For Late-Stage Trial For Treatment Of Recurrent Glioblastoma
27/09/2023 22:34
Sept 27 (Reuters) - Sagimet Biosciences Inc SGMT.O :
* SAGIMET BIOSCIENCES ANNOUNCES COMPLETION OF ENROLLMENT OF
120
PATIENTS FOR PHASE 3 CLINICAL TRIAL BY ITS PARTNER ASCLETIS OF
DENIFANSTAT COMBINED WITH BEVACIZUMAB FOR TREATMENT OF RECURRENT
GLIOBLASTOMA
* SAGIMET BIOSCIENCES INC - BIOPSY RESULTS ARE EXPECTED IN
Q1 OF
2024
* SAGIMET: SEES TO REPORT PHASE 1 CLINICAL TRIAL RESULTS
CHARACTERIZING PHARMACOKINETIC PROFILE OF DENIFANSTAT IN
PATIENTS WITH IMPAIRED HEPATIC FUNCTION IN Q1 2024
Source text for Eikon: ID:nGNX5SvMhx
Further company coverage: SGMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage